TABLE 3.

Relationship Between BRAF V600E Alone, TERT C228T Alone, or Their Coexistence and Loss of RAI Avidity in Recurrent PTC

	Loss of RAI		Odds ratio
Tumor type and mutation status	n	P	Unadjusted	Adjusted*
All PTC	103/164 (62.8)
No mutation	16/53 (30.2)	Reference	1.00	1.00
BRAF V600E alone	49/68 (72.1)	<0.001	5.96 (2.71–13.14)	5.63 (2.49–12.72)
TERT C228T alone	5/9 (55.6)	0.137	2.89 (0.69–12.20)	2.18 (0.39–12.25)
BRAF + TERT mutations	33/34 (97.1)	<0.001	76.31 (9.59–607.18)	127.69 (11.45–1,423.89)
CPTC	81/126 (64.3)
No mutation	8/36 (22.2)	Reference	1.00	1.00
BRAF V600E alone	43/59 (72.9)	<0.001	9.41 (3.55–24.89)	8.83 (3.23–24.09)
TERT C228T alone	2/3 (66.7)	0.090	7.00 (0.56–87.50)	28.89 (0.77–1,079.55)
BRAF + TERT mutations	28/28 (100.00)	<0.001	118.95 (18.10–+∞)	162.36 (18.63–+∞)

^*Adjusted for patient age and sex.

CPTC = conventional PTC.

TERT promoter mutations here included, collectively, TERT C228T and TERT C250T. Data in parentheses are percentages or 95% CIs.